January 23, 2018

VIA EDGAR

Mr. Jeffrey Gabor

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Melinta Therapeutics, Inc.

Registration Statement on Form S-3 (Registration No. 333-222485)

Dear Mr. Gabor:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Melinta Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 (as amended to date, the “Registration Statement”) be accelerated to Wednesday, January 24, 2018 at 4:30 p.m., Eastern Standard Time, or as soon as practicable thereafter.

The Company hereby acknowledges that:

• should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

• the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the accuracy and adequacy of the disclosure in the filing; and

• the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Sincerely,
MELINTA THERAPEUTICS, INC.
By:	/s/ Paul Estrem
Name:	Paul Estrem
Title:	Chief Financial Officer
cc:	Sean M. Ewen, Esq.